INTELLIGENT BIO SOLUTIONS INC
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Other Comprehensive Loss
| Three Months ended March 31, | Nine Months ended March 31, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | $823,800 | $457,058 | $2,383,957 | $813,737 |
| Cost of revenue (exclusive of amortization shown separately below) | (645,311) | (424,009) | (1,773,889) | (536,644) |
| Gross profit | 178,489 | 33,049 | 610,068 | 277,093 |
| Other income: | ||||
| Government support income | 83,842 | 117,680 | 346,917 | 698,625 |
| Operating expenses: | ||||
| Selling, general and administrative expenses | (2,425,830) | (1,898,754) | (6,587,934) | (5,594,461) |
| Development and regulatory approval expenses | (471,313) | (299,898) | (923,712) | (380,363) |
| Depreciation and amortization | (318,923) | (398,986) | (916,796) | (797,142) |
| Goodwill impairment | - | (4,096,490) | - | (4,096,490) |
| Total operating expenses | (3,216,066) | (6,694,128) | (8,428,442) | (10,868,456) |
| Loss from operations | (2,953,735) | (6,543,399) | (7,471,457) | (9,892,738) |
| Other income (expense), net: | ||||
| Interest expense | (42,674) | (86,125) | (112,590) | (163,957) |
| Realized foreign exchange income/(loss) | (996) | 7,212 | (1,551) | (8,936) |
| Fair value gain on revaluation of financial instrument | - | 269,787 | 175,738 | 2,062,878 |
| Interest income | 10,640 | 508 | 14,288 | 9,587 |
| Total other income (expense), net | (33,030) | 191,382 | 75,885 | 1,899,572 |
| Net loss | (2,986,765) | (6,352,017) | (7,395,572) | (7,993,166) |
| Net loss attributable to non-controlling interest | (9,098) | (8,111) | (23,060) | (20,367) |
| Net loss attributable to Intelligent Bio Solutions Inc. | $(2,977,667) | $(6,343,906) | $(7,372,512) | $(7,972,799) |
| Other comprehensive income/(loss), net of tax: | ||||
| Foreign currency translation gain/ (loss) | (144,026) | (77,787) | (86,909) | 148,251 |
| Total other comprehensive income/(loss) | (144,026) | (77,787) | (86,909) | 148,251 |
| Comprehensive loss | (3,130,791) | (6,429,804) | (7,482,481) | (7,844,915) |
| Comprehensive loss attributable to non-controlling interest | (9,098) | (8,111) | (23,060) | (20,367) |
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | (3,121,693) | (6,421,693) | (7,459,421) | (7,824,548) |
| Net loss per share, basic and diluted* | $(1.43) | $(68.67) | $(6.64) | $(104.04) |
| Weighted average shares outstanding, basic and diluted* | 2,079,864 | 92,389 | 1,110,089 | 76,629 |
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.